Sunshine Biopharma Files 8-K on Corporate Changes
Ticker: SBFMW · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financial-reporting, amendment
Related Tickers: SBFM
TL;DR
Sunshine Biopharma filed an 8-K on Aug 7th for corporate changes & financials.
AI Summary
Sunshine Biopharma, Inc. filed an 8-K on August 12, 2024, reporting an amendment to its articles of incorporation and financial statements. The filing pertains to events occurring on August 7, 2024, and includes information about common stock and purchase warrants.
Why It Matters
This filing indicates corporate actions and financial reporting by Sunshine Biopharma, which could impact investors' understanding of the company's structure and financial health.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for corporate actions and financial statements, not indicating immediate significant risk.
Key Numbers
- 20240807 — Event Date (The earliest event date reported in the filing.)
- 20240812 — Filing Date (The date the 8-K was officially filed with the SEC.)
Key Players & Entities
- Sunshine Biopharma, Inc. (company) — Registrant
- August 7, 2024 (date) — Date of earliest event reported
- August 12, 2024 (date) — Date of report filing
- Colorado (jurisdiction) — State of incorporation
- 001-41282 (company_id) — Commission File Number
- 20-5566275 (company_id) — IRS Employer ID Number
FAQ
What specific amendments were made to the articles of incorporation?
The filing indicates amendments to articles of incorporation and bylaws, but the specific details of these amendments are not provided in this excerpt.
What financial statements are included in this filing?
The filing states that financial statements and exhibits are included, but the specific statements are not detailed in this excerpt.
What is the significance of the 'CommonStockMember' and 'CommonStockPurchaseWarrantsMember' entries?
These entries, associated with the dates 2024-08-07, indicate that the filing pertains to the company's common stock and common stock purchase warrants.
What was Sunshine Biopharma's former company name?
Sunshine Biopharma, Inc. was formerly known as Mountain West Business Solutions, Inc., with name changes occurring on October 30, 2007, and June 7, 2007.
What is the company's primary business sector?
Sunshine Biopharma, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-08-12 16:05:09
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Filing Documents
- sunshine_8k.htm (8-K) — 27KB
- sunshine_ex0301.htm (EX-3.1) — 9KB
- 0001683168-24-005496.txt ( ) — 252KB
- sbfm-20240807.xsd (EX-101.SCH) — 3KB
- sbfm-20240807_def.xml (EX-101.DEF) — 26KB
- sbfm-20240807_lab.xml (EX-101.LAB) — 36KB
- sbfm-20240807_pre.xml (EX-101.PRE) — 25KB
- sunshine_8k_htm.xml (XML) — 6KB
03 Amendments to Articles of Incorporation
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Effective August 7, 2024, Sunshine Biopharma, Inc. (the "Company") filed a certificate of amendment to its articles of incorporation with the Secretary of State of Colorado to effect a 1-for-20 reverse split of the Company's common stock. The market effective date of the reverse split was August 8, 2024.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment 104 Cover Page Interactive Data File (formatted in Inline XBRL). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 12, 2024 SUNSHINE BIOPHARMA, INC. By: /s/ Dr. Steve N. Slilaty Dr. Steve N. Slilaty, Chief Executive Officer 3